|Articles|February 1, 1997

Looking Beyond the Formulary Budget: Cost Analysis and a Psychiatric Perspective
Volume 3
Issue 2 Suppl

Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Author(s)Gary L. Viale, PharmD

Download PDF: Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Articles in this issue

over 29 years ago

Article

Introduction: Looking Beyond the Formulary Budget

over 29 years ago

Article

Looking Beyond the Formulary Budget in Cost-Benefit Analysis

over 29 years ago

Article

Retrospective Analysis of the Effect of Risperidone on Clinical Outcome

over 29 years ago

Article

Newer Antipsychotic Medications: Discussions

over 29 years ago

Article

Bibliography

over 29 years ago

Article

Participants

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man with chest pain | Image credit: Liubomir - stock.adobe.com

The Right Care Initiative: Promoting Accountable Care to Prevent Cardiovascular Death

ByHector P. Rodriguez, PhD, MPH, Hattie R. Hanley, MPP,Stephen M. Shortell, PhD, MBA, MPH

September 15th 2026

Pregnant woman | Image credit: pressmaster - stock.adobe.com

Early Signs of Success for Missouri’s New Notification of Pregnancy

ByAbigail R. Barker, PhD,Nadim Kanafani, MD,Kelley M. Peters, MS, RN, BSN,Rashmi Srivastava, MD, BS

September 15th 2026

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Articles in this issue

Related Content

The Right Care Initiative: Promoting Accountable Care to Prevent Cardiovascular Death

Early Signs of Success for Missouri’s New Notification of Pregnancy

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Trending on AJMC

FDA Clears First Alzheimer Blood Test for Adults as Young as 40

5 Things to Know About the 2026 ESC Heart Failure Guidelines

FDA Shortens Tarlatamab Monitoring, Widens Access to SCLC Care

MFN Drug Agreements Could Raise Prices Worldwide

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD